$1.28
26.73% yesterday
Nasdaq, Sep 03, 10:18 pm CET
ISIN
US82024L1035
Symbol
STTK

Shattuck Labs Inc Stock price

$1.28
+0.54 72.34% 1M
+0.06 4.92% 6M
+0.07 5.79% YTD
-2.15 62.68% 1Y
-1.97 60.62% 3Y
-15.72 92.47% 5Y
-15.72 92.47% 10Y
-15.72 92.47% 20Y
Nasdaq, Closing price Wed, Sep 03 2025
+0.27 26.73%
ISIN
US82024L1035
Symbol
STTK
Industry

Key metrics

Basic
Market capitalization
$48.4m
Enterprise Value
$-2.1m
Net debt
positive
Cash
$50.5m
Shares outstanding
47.9m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
16.1 | -
EV/Sales
negative | -
EV/FCF
0.0
P/B
0.9
Financial Health
Equity Ratio
87.5%
Return on Equity
-94.7%
ROCE
-110.1%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$3.0m | $0.0
EBITDA
$-61.2m | $-63.5m
EBIT
$-65.0m | $-58.0m
Net Income
$-61.5m | $-44.8m
Free Cash Flow
$-55.9m
Growth (TTM | estimate)
Revenue
-27.4% | -100.0%
EBITDA
29.3% | 17.0%
EBIT
28.2% | 27.8%
Net Income
27.9% | 40.6%
Free Cash Flow
11.6%
Margin (TTM | estimate)
Gross
-
EBITDA
-2,042.8% | -
EBIT
-2,168.2%
Net
-2,052.5% | -
Free Cash Flow
-1,866.6%
More
EPS
$-1.2
FCF per Share
$-1.2
Short interest
4.0%
Employees
44
Rev per Employee
$130.0k
Show more

Is Shattuck Labs Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,003 stocks worldwide.

Shattuck Labs Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

11 Analysts have issued a Shattuck Labs Inc forecast:

7x Buy
64%
4x Hold
36%

Analyst Opinions

11 Analysts have issued a Shattuck Labs Inc forecast:

Buy
64%
Hold
36%

Financial data from Shattuck Labs Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
3 3
27% 27%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 18 18
10% 10%
589%
- Research and Development Expense 50 50
33% 33%
1,677%
-61 -61
29% 29%
-2,041%
- Depreciation and Amortization 3.76 3.76
5% 5%
125%
EBIT (Operating Income) EBIT -65 -65
28% 28%
-2,166%
Net Profit -62 -62
28% 28%
-2,050%

In millions USD.

Don't miss a Thing! We will send you all news about Shattuck Labs Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Shattuck Labs Inc Stock News

Neutral
GlobeNewsWire
9 days ago
— Aggregate net proceeds from private placement expected to fund SL-325 through multiple Phase 2 clinical trials, including in Inflammatory Bowel Disease (IBD) and potentially another autoimmune disease —
Neutral
GlobeNewsWire
13 days ago
– SL-325 is a potentially first-in-class DR3 antagonist antibody being developed for the treatment of Inflammatory Bowel Disease (IBD) and other inflammatory and immune-mediated diseases –
Neutral
GlobeNewsWire
21 days ago
– Submitted Investigational New Drug (IND) application to evaluate SL-325 in a Phase 1 clinical trial in healthy volunteers; clearance expected in Q3 2025 –
More Shattuck Labs Inc News

Company Profile

Shattuck Labs, Inc. engages in the research and development of Agonist Redirected Checkpoint (ARC) platform. It develops a novel class of biologic medicines, capable of multifunctional activity, with potential applications in oncology and autoimmune diseases. The company was founded by Josiah C. Hornblower and Taylor Schreiber in 2016 and is headquartered in Austin, TX.

Head office United States
CEO Taylor Schreiber
Employees 44
Founded 2016
Website www.shattucklabs.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today